Clinic Roundup
Merrimack Pharmaceuticals Inc., of Cambridge, Mass., enrolled its last patient in a Phase II, open-label, randomized trial of MM-121, a human monoclonal antibody, in combination with paclitaxel, compared to paclitaxel alone in advanced ovarian cancers.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.